Abstract
Lung cancer is a complex and often fatal disease. The recent discoveries of activating mutations in EGFR and fusion genes involving ALK are milestones in a trend towards more personalized medicine in lung cancer. Targeting these alterations leads to survival benefit for our patients. EGFR and ALK testing can nowadays be considered as standard practice. Newer targets in the fight against lung cancer are discussed, such as MET and ROS.1 in adenocarcinoma. Also, new targets for squamous cell carcinoma are emerging, such as FGFR and DDR2.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
